Overall market sentiment has been down on Inhibrx Inc (INBX) stock lately. INBX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Inhibrx Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on INBX!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With INBX Stock Today?
Inhibrx Inc (INBX) stock is trading at $24.97 as of 3:03 PM on Thursday, May 11, a drop of -$0.89, or -3.44% from the previous closing price of $25.86. The stock has traded between $24.33 and $26.50 so far today. Volume today is less active than usual. So far 267,728 shares have traded compared to average volume of 418,881 shares.
More About Inhibrx Inc
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Click Here to get the full Stock Report for Inhibrx Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
